Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
CNY 6.71
(0.3%)
CNY 6.71
(0.3%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 115.04 Million CNY | 2909.72% |
| 2022 | 3.82 Million CNY | -53.65% |
| 2021 | 8.24 Million CNY | 6.55% |
| 2020 | 7.74 Million CNY | 0.0% |
| 2019 | - CNY | -100.0% |
| 2018 | 150 Million CNY | -58.33% |
| 2017 | 360 Million CNY | -6.25% |
| 2016 | 384 Million CNY | 6.79% |
| 2015 | 359.59 Million CNY | 0.44% |
| 2014 | 358.02 Million CNY | 0.42% |
| 2013 | 356.53 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | -100.0% |
| 2008 | 29.01 Million CNY | -23.65% |
| 2007 | 38 Million CNY | -33.33% |
| 2006 | 57 Million CNY | -1.72% |
| 2005 | 58 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.55 Million CNY | -99.99% |
| 2024 Q2 | 113.41 Million CNY | 5493.92% |
| 2024 Q1 | 2.02 Million CNY | -98.24% |
| 2023 Q2 | 2.76 Million CNY | -11.78% |
| 2023 Q3 | 2.4 Million CNY | -13.04% |
| 2023 FY | 115.04 Million CNY | 2909.72% |
| 2023 Q4 | 115.04 Million CNY | 4676.65% |
| 2023 Q1 | 3.13 Million CNY | -17.87% |
| 2022 Q3 | 4.22 Million CNY | -24.66% |
| 2022 Q2 | 5.6 Million CNY | -34.38% |
| 2022 FY | 3.82 Million CNY | -53.65% |
| 2022 Q1 | 8.54 Million CNY | 3.58% |
| 2022 Q4 | 3.82 Million CNY | -9.5% |
| 2021 Q3 | 7.63 Million CNY | 10.1% |
| 2021 FY | 8.24 Million CNY | 6.55% |
| 2021 Q2 | 6.93 Million CNY | 305.96% |
| 2021 Q1 | 1.7 Million CNY | -77.93% |
| 2021 Q4 | 8.24 Million CNY | 7.99% |
| 2020 Q2 | 7.74 Million CNY | 0.0% |
| 2020 Q4 | 7.74 Million CNY | 0.0% |
| 2020 Q1 | 7.74 Million CNY | 0.0% |
| 2020 FY | 7.74 Million CNY | 0.0% |
| 2020 Q3 | 7.74 Million CNY | 0.0% |
| 2019 Q4 | - CNY | 0.0% |
| 2019 FY | - CNY | -100.0% |
| 2019 Q3 | - CNY | 0.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q2 | 450 Million CNY | 0.0% |
| 2018 Q3 | 150 Million CNY | -66.67% |
| 2018 Q4 | 150 Million CNY | 0.0% |
| 2018 FY | 150 Million CNY | -58.33% |
| 2018 Q1 | 450 Million CNY | 25.0% |
| 2017 Q2 | 360 Million CNY | 0.0% |
| 2017 Q1 | 360 Million CNY | -6.25% |
| 2017 FY | 360 Million CNY | -6.25% |
| 2017 Q4 | 360 Million CNY | 0.0% |
| 2017 Q3 | 360 Million CNY | 0.0% |
| 2016 Q3 | 360 Million CNY | 0.0% |
| 2016 Q1 | 360 Million CNY | 0.11% |
| 2016 Q4 | 384 Million CNY | 6.67% |
| 2016 Q2 | 360 Million CNY | 0.0% |
| 2016 FY | 384 Million CNY | 6.79% |
| 2015 Q3 | 359.19 Million CNY | 0.11% |
| 2015 Q4 | 359.59 Million CNY | 0.11% |
| 2015 Q1 | 358.39 Million CNY | 0.11% |
| 2015 FY | 359.59 Million CNY | 0.44% |
| 2015 Q2 | 358.79 Million CNY | 0.11% |
| 2014 Q2 | 357.26 Million CNY | -14.32% |
| 2014 Q3 | 357.64 Million CNY | 0.11% |
| 2014 Q4 | 358.02 Million CNY | 0.11% |
| 2014 FY | 358.02 Million CNY | 0.42% |
| 2014 Q1 | 416.99 Million CNY | 16.96% |
| 2013 FY | 356.53 Million CNY | 0.0% |
| 2013 Q1 | 355.44 Million CNY | 0.0% |
| 2013 Q4 | 356.53 Million CNY | 0.1% |
| 2013 Q2 | 355.82 Million CNY | 0.1% |
| 2013 Q3 | 356.17 Million CNY | 0.1% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2010 Q3 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2010 Q1 | - CNY | 0.0% |
| 2009 FY | - CNY | -100.0% |
| 2009 Q4 | - CNY | -100.0% |
| 2009 Q3 | 35 Million CNY | 75.0% |
| 2009 Q1 | - CNY | -100.0% |
| 2009 Q2 | 20 Million CNY | 0.0% |
| 2008 Q4 | 29.01 Million CNY | 0.16% |
| 2008 Q3 | 28.96 Million CNY | -40.98% |
| 2008 Q1 | 49.89 Million CNY | 31.31% |
| 2008 FY | 29.01 Million CNY | -23.65% |
| 2008 Q2 | 49.07 Million CNY | -1.64% |
| 2007 Q4 | 38 Million CNY | 0.0% |
| 2007 FY | 38 Million CNY | -33.33% |
| 2006 FY | 57 Million CNY | -1.72% |
| 2005 FY | 58 Million CNY | 0.0% |